← Leaderboards
Joseph Moeller Schinaman
Petri Bio Llc
$2,532,245
Attributed
$2,532,245
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,532,245 · 2
By mechanism
R44$2,170,314 · 1
R43$361,931 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “In Vitro Testing”
- Leonard Freedman · Leidos Biomedical Research, Inc.$245,503,168
- Lynn Briscoe · Leidos Biomedical Research, Inc.$95,408,471
- Leonard Freedmand · Leidos Biomedical Research, Inc.$55,464,221
- Timothy Fouts · Advanced Bioscience Laboratories, Inc.$42,191,190
- Tony Moody · Duke University$34,777,314
- John Damon Chodera · Sloan-Kettering Inst Can Research$31,137,784
Research focus
In Vitro TestingIn VivoIn SilicoIn VitroGut MicrobiomeHomocystinuriaEye CenterDietary RestrictionExpression VectorEnzyme TherapyGenesBiomaterial CompatibilityCatalysisHomocysteineDietary SupplementationDetectionBetaineDietary IntakeDoctor Of PhilosophyEnsureEnzymesCystathionineAmino AcidsLens
Grant awards (4)
Live microbial therapeutics: an enhanced treatment paradigm for classical homocystinuria$1,169,818
R44 · FY2025 · HD · contact PI
Live microbial therapeutics: an enhanced treatment paradigm for classical homocystinuria$1,000,496
R44 · FY2024 · HD · contact PI
Live microbial therapeutics for enzyme replacement therapy against homocystinuria$55,000
R43 · FY2022 · HD · contact PI
Live microbial therapeutics for enzyme replacement therapy against homocystinuria$306,931
R43 · FY2021 · HD · contact PI